BR112023004713A2 - Formas sólidas de um inibidor de cdk4 - Google Patents

Formas sólidas de um inibidor de cdk4

Info

Publication number
BR112023004713A2
BR112023004713A2 BR112023004713A BR112023004713A BR112023004713A2 BR 112023004713 A2 BR112023004713 A2 BR 112023004713A2 BR 112023004713 A BR112023004713 A BR 112023004713A BR 112023004713 A BR112023004713 A BR 112023004713A BR 112023004713 A2 BR112023004713 A2 BR 112023004713A2
Authority
BR
Brazil
Prior art keywords
solid forms
cdk4 inhibitor
pharmaceutical compositions
forms
cdk4
Prior art date
Application number
BR112023004713A
Other languages
English (en)
Inventor
Dewitt Clark Wesley
Gail Deal Judith
Matthew Samas Brian
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112023004713A2 publication Critical patent/BR112023004713A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMAS SÓLIDAS DE UM INIBIDOR DE CDK4. A presente invenção refere-se a formas cristalinas e amorfas de 1,5-anidro-3-({5-cloro-4-[4-fluoro-2-(2-hidroxipropan-2-il)-1-(propan-2-il)-1H-benzimidazol-6-il]pirimidin-2-il}amino)-2,3-dideóxi-D-treo-pentitol, a composições farmacêuticas que compreendem tais formas sólidas, e ao uso de tais formas sólidas e composições farmacêuticas para o tratamento de câncer.
BR112023004713A 2020-09-15 2021-09-13 Formas sólidas de um inibidor de cdk4 BR112023004713A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078636P 2020-09-15 2020-09-15
US202163240268P 2021-09-02 2021-09-02
PCT/IB2021/058320 WO2022058871A1 (en) 2020-09-15 2021-09-13 Solid forms of a cdk4 inhibitor

Publications (1)

Publication Number Publication Date
BR112023004713A2 true BR112023004713A2 (pt) 2023-04-18

Family

ID=78000744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004713A BR112023004713A2 (pt) 2020-09-15 2021-09-13 Formas sólidas de um inibidor de cdk4

Country Status (10)

Country Link
US (1) US20230357211A1 (pt)
EP (1) EP4214202A1 (pt)
JP (2) JP7260606B2 (pt)
KR (1) KR20230069983A (pt)
AU (1) AU2021345531B2 (pt)
BR (1) BR112023004713A2 (pt)
CA (1) CA3195063A1 (pt)
MX (1) MX2023003054A (pt)
TW (2) TWI809503B (pt)
WO (1) WO2022058871A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023100070A1 (en) * 2021-12-02 2023-06-08 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
CR20190062A (es) 2016-08-15 2019-05-22 Pfizer Inhibidores de cdk2/4/6
KR102661053B1 (ko) * 2018-04-26 2024-04-26 화이자 인코포레이티드 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체

Also Published As

Publication number Publication date
CA3195063A1 (en) 2022-03-24
JP2022186995A (ja) 2022-12-15
KR20230069983A (ko) 2023-05-19
AU2021345531A1 (en) 2023-04-20
US20230357211A1 (en) 2023-11-09
TW202216698A (zh) 2022-05-01
TW202334125A (zh) 2023-09-01
JP7260606B2 (ja) 2023-04-18
WO2022058871A1 (en) 2022-03-24
MX2023003054A (es) 2023-04-05
JP2022049005A (ja) 2022-03-28
EP4214202A1 (en) 2023-07-26
TWI809503B (zh) 2023-07-21
JP7291839B2 (ja) 2023-06-15
AU2021345531B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
BR112023004713A2 (pt) Formas sólidas de um inibidor de cdk4
CL2008000862A1 (es) Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1.
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
CR20110016A (es) Compuestos quimicos 251
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR0308653A (pt) Cristais de derivado de benzeno de glicopiranosiloxibenzila
BRPI0617159B8 (pt) compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
BRPI0717970B8 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
ECSP109500A (es) Compuestos y composiciones como inhibidores de proteína quinasa
BR112020001850A8 (pt) Mistura antimicrobiana, composição, processo de tratamento cosmético, processo para conservar uma composição e uso de uma mistura antimicrobiana
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
CL2009000579A1 (es) Formulacion herbicida que comprende piroxasulfona y metazaclor; uso de dicha formulacion y metodo que la emplea para combatir vegetacion indeseable.
NI202100018A (es) Moduladores de la expresión de pnpla3
BR112022019492A2 (pt) Inibidores de rip1k
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
NI202000085A (es) Moduladores de la expresión de apol1
AR056049A1 (es) 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.